Apellis soars as Alexion rival outshines blockbuster standard bearer Soliris — then fresh doubts scuttle spike

John Carroll

Editor & Founder

Apellis went gunning for Alexion’s star drug Soliris in a head-to-head PNH Phase III. And the smaller biotech said Tuesday morning that they came out with a clear win.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Apellis soars as Alexion rival outshines blockbuster standard bearer Soliris — then fresh doubts scuttle spike

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Senior Manager, Regulatory Affairs

Adicet Bio

Redwood City, CA, USA

Autoimmune patients in CAR-T study see striking improvements across lupus and other diseases

As cash runs tight, bluebird plunges after pricing sickle cell gene therapy well above competitor and failing to win ...

Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question

FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR

How one lab's decadeslong search for the 'holy grail' of sickle cell led to the first CRISPR therapy

Solid Tumors: The Next Frontier of Cancer Immuno-therapy

Apel­lis soars as Alex­ion ri­val out­shines block­buster stan­dard bear­er Soliris — then fresh doubts scut­tle spike

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Adicet Bio

Redwood City, CA, USA

Apellis soars as Alexion rival outshines blockbuster standard bearer Soliris — then fresh doubts scuttle spike